The United States surpassed 11 million coronavirus cases on Sunday, according to data from Johns Hopkins University. The push to develop a vaccine that can neutralize the coronavirus has brought good news from the pharmaceutical industry. Moderna, a Boston Based Pharma company, has released its preliminary analysis of its vaccine, which is 94% effective.
Moderna’s Phase 3 clinical study is being conducted in collaboration with NIH and BARDA with an Expected 30,000 participants in the U.S. They have released preliminary data, which shows more than 94% efficacy on the trails they have collected so far.
The Pfizer vaccine announced last week, and the Moderna vaccine announcement has given everyone hope that this will start turning around in a few months. The light at the end of the tunnel has got a little brighter.
The Boston Based pharmaceutical company says that there are very few side effects in the vaccine. there is a little pain in the injection site after the second dose, as there will be two doses for the vaccine, there might be a headache, possibly fatigue, and muscle pain.
According to the company, the vaccine does not contain any part of the actual coronavirus, so you cant get infected by it. Moderna’s mRNA-1273 uses the mRNA (messenger RNA) delivery platform to encode for an S-2P immunogen. The investigational vaccine directs the body’s cells to express the spike protein to elicit a broad immune response.
Approximately 20 million of the vaccine doses are ready to ship across the united states by the end of the year. Dr. Fauchi says, “we are finally headed in the right direction.”
“I had been saying I would be satisfied with a 75 percent effective vaccine. Aspirationally, you would like to see 90, 95 percent, but I wasn’t expecting it. I thought we’d be good, but 94.5 percent is very impressive.” Dr. Anthony S. Fauci, director of the Institute
How does this compare to the Pfizer vaccine, which was announced last week which is said to be 90% effective, well for one, it looks like that Moderna vaccine might be able to be transported and stored a little bit easier because, with the Pizer vaccine, it has to be stored at – 94 Degrees F with the Moderna vaccine you can store it in your refrigerator.
Pfizer did not take any money from the U.S. government to develop or test its vaccine. But Operation Warp Speed has promised Pfizer $1.95 billion to provide 100 million doses, which comes out to $19.50 per dose.
Moderna announced on Oct. 22 that it had completed enrollment of its 30,000-person study and that 25,650 participants had already received two shots. The company had slowed enrollment in September to ensure diversity among participants. It ultimately included 37 percent from communities of color and 42 percent from populations considered at high risk because they were over 65 or had conditions like diabetes, obesity, or heart disease.
Moderna will apply for an Emergency usage of the vaccine with the FDA based on two months of its data in the coming weeks.